Skip to main content

Advertisement

Table 1 Patient characteristics (detailed data on patients in subgroups related to TP53 status and the chemotherapy type, as well as the number of patients at risk of recurrence and death in each subgroup at different follow-up points).

From: TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study

  All patients, N = 452 TP53(-) group, N = 186 TP53(+) group, N = 266
Chemotherapy PC/PAC TP PC/PAC TP PC/PAC TP
  N = 253 N = 199 N = 104 N = 82 N = 149 N = 117
Age       
   Range 24–77 20–78 24–76 20–74 25–77 33–78
   mean (st.dev.) 53.9 (10.6) 54.6 (11.2) 53 (11.3) 55 (11.8) 54.5 (10.1) 54.4 (10.8)
FIGO stage       
   IIB, IIC 18 (7%) 10 (5%) 6 (6%) 6 (7%) 12 (8%) 4 (3%)
   IIIA, IIIB 56 (22%) 28 (14%) 23 (22%) 10 (12%) 33 (22%) 18 (15%)
   IIIC 145 (57%) 141 (71%) 60 (58%) 61 (74%) 86 (58%) 80 (68%)
   IV 33 (13%) 20 (10%) 15 (14%) 5 (6%) 18 (12%) 15 (13%)
Residual Tumor Size       
   0 53 (21%) 37 (19%) 18 (17%) 16 (20%) 35 (23%) 21 (18%)
   >0 ≤ 2 cm 65 (26%) 81 (41%) 30 (29%) 35 (43%) 35 (23%) 46 (39%)
   >2 cm 135 (53%) 81 (41%) 56 (54%) 31 (38%) 79 (53%) 50 (43%)
Histological Type       
   Serous 199 (79%) 147 (74%) 72 (69%) 58 (71%) 127 (85%) 89 (76%)
   Endometrioid, Clear cell 26 (10%) 13 (7%) 21 (20%) 8 (10%) 5 (3%) 5 (4%)
   Undifferentiated 14 (5%) 21 (10%) 5 (5%) 7 (9%) 9 (6%) 14 (12%)
   Other 14 (5%) 18 (9%) 6 (6%) 9 (11%) 8 (5%) 9 (8%)
Tumor grade       
   G2 31 (12%) 26 (13%) 20 (19%) 15 (18%) 11 (7%) 11 (9%)
   G3 158 (62%) 115 (58%) 59 (57%) 44 (54%) 99 (66%) 71 (61%)
   G4 64 (25%) 58 (29%) 25 (24%) 23 (28%) 39 (26%) 35 (30%)
TP53 accumulation       
   Negative 104 (41%) 82 (41%) 100% 100% 0 0
   Positive 149 (59%) 117 (59%) 0 0 100% 100%
Response to chemotherapy       
   complete remission 135 (53%) 131 (66%) 53 (51%) 51 (62%) 82 (55%) 80 (68%)
   partial remission/no change1 52 (21%) 62 (32%) 18 (17%) 31 (39%) 34 (23%) 31 (27%)
   progression 66 (26%) 6 (3%) 33 (32%) 0 33 (22%) 6 (5%)
Platinum sensitive 109 (43%) 112 (56%) 46 (44%) 42 (51%) 63 (42%) 70 (60%)
Platinum highly sensitive 43 (17%) 39 (20%) 18 (17%) 12 (15%) 25 (17%) 27 (23%)
Platinum resistant 144 (57%) 87 (44%) 58 (56%) 40 (49%) 86 (58%) 47 (40%)
Follow up time for alive patients N = 30 N = 85 N = 11 N = 36 N = 19 N = 49
Range (months) 10–195 12.7–88.5 10–195 12.7–88.5 33–173.3 12.8–85.1
median 75.5 36.8 81.1 39.4 74.2 33.4
Number of patients at risk (OS)2       
   1 year 212 (84%) 187 (94%) 82 (80%) 78 (95%) 130 (87%) 109 (93%)
   2 years 137 (54%) 132 (74%) 54 (53%) 58 (75%) 83 (56%) 75 (74%)
   3 years 90 (36%) 70 (51%) 38 (38%) 26 (47%) 52 (35%) 44 (53%)
   4 years 61 (26%) 45 (39%) 23 (24%) 18 (39%) 38 (27%) 27 (39%)
   5 years 44 (21%) 28 (31%) 17 (19%) 12 (34%) 27 (22%) 16 (29%)
Follow up for disease-free patients3 N = 23 N = 29 N = 10 N = 10 N = 13 N = 19
Range (months) 8.7–187.3 14.6–80.6 15.2–187.3 14.6–69.3 8.7–164.7 14.8–80.6
median 76.2 38.1 68.6 33.6 82.8 38.2
Number of patients at risk (DFS)2       
   1 year 72 (54%) 75 (56%) 33 (62%) 27 (53%) 39 (49%) 48 (59%)
   2 years 43 (33%) 39 (33%) 18 (35%) 12 (27%) 25 (31%) 27 (38%)
   3 years 34 (26%) 23 (26%) 14 (27%) 7 (21%) 20 (25%) 16 (28%)
   4 years 24 (20%) 14 (21%) 11 (23%) 5 (21%) 13 (18%) 9 (21%)
   5 years 17 (17%) 6 (14%) 8 (21%) 2 (11%) 9 (15%) 4 (21%)
  1. PC – cyclophosphamide and cisplatin, PAC – PC plus doxorubicin, TP-taxane-platinum therapy; 1we have combined these responses because it was not always possible to have objective measures of the disease in the restrospective study; OS-overall survival, DFS – disease free survival; 2based on Kaplan-Meier estimator, 3 those who had complete remission only